Brief: Annexon Topline Data From Archer Phase 2 Trial Of ANX007 In Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation Of Visual Function

Annexon

24/05/2023 22:18

May 24 (Reuters) - Annexon Inc  ANNX.O :
    * ANNEXON TOPLINE DATA FROM ARCHER PHASE 2 TRIAL OF ANX007
IN
GEOGRAPHIC ATROPHY DEMONSTRATED STATISTICALLY SIGNIFICANT,
DOSE-DEPENDENT PRESERVATION OF VISUAL FUNCTION
    * ANNEXON INC: REDUCTION IN RATE OF GEOGRAPHIC ATROPHY
LESION
GROWTH DID NOT REACH STATISTICAL SIGNIFICANCE
    * ANNEXON INC: COMPANY PLANS TO ENGAGE WITH REGULATORY
AGENCIES TO
DETERMINE OPTIMAL PATH FORWARD FOR ANX007
    * ANNEXON INC - ANX007 WAS GENERALLY WELL TOLERATED AS BOTH
A
MONTHLY AND EVERY-OTHER-MONTH TREATMENT

Source text for Eikon:  ID:nGNX31TbBh 
Further company coverage:  ANNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))